stoxline Quote Chart Rank Option Currency Glossary
  
Zynex, Inc. (ZYXI)
11.38  -0.07 (-0.61%)    04-19 16:00
Open: 11.42
High: 11.7
Volume: 181,319
  
Pre. Close: 11.45
Low: 11.24
Market Cap: 366(M)
Technical analysis
2024-04-19 5:13:27 PM
Short term     
Mid term     
Targets 6-month :  14.53 1-year :  15.4
Resists First :  12.44 Second :  13.18
Pivot price 12.12
Supports First :  11.23 Second :  9.35
MAs MA(5) :  11.8 MA(20) :  12.23
MA(100) :  11.45 MA(250) :  9.91
MACD MACD :  -0.3 Signal :  -0.2
%K %D K(14,3) :  12.9 D(3) :  19.5
RSI RSI(14): 33.7
52-week High :  14.75 Low :  6.88
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ZYXI ] has closed below the lower bollinger band by 6.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 18.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.72 - 11.8 11.8 - 11.85
Low: 11.07 - 11.17 11.17 - 11.23
Close: 11.26 - 11.4 11.4 - 11.5
Company Description

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Headline News

Thu, 18 Apr 2024
Zynex Sets First Quarter 2024 Earnings Call - BioSpace

Thu, 14 Mar 2024
Zynex Inc. at a Crossroads: $60 Million Convertible Notes Pose Liquidity and Dilution Risks - TipRanks.com - TipRanks

Fri, 01 Mar 2024
Zynex Inc Down 6.55% To $12.67 After Earnings Miss - InvestorsObserver

Thu, 29 Feb 2024
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates - Yahoo Finance

Thu, 29 Feb 2024
Zynex, Inc. (ZYXI) Q4 2023 Earnings Call Transcript - Seeking Alpha

Thu, 29 Feb 2024
Zynex Reports Fourth Quarter and Full Year 2023 Financial Results - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Distribution
Shares Out 32 (M)
Shares Float 16 (M)
Held by Insiders 51.1 (%)
Held by Institutions 31.2 (%)
Shares Short 5,750 (K)
Shares Short P.Month 5,880 (K)
Stock Financials
EPS 0.27
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.37
Profit Margin 5.2 %
Operating Margin 4.8 %
Return on Assets (ttm) 5.3 %
Return on Equity (ttm) 17.2 %
Qtrly Rev. Growth -3.1 %
Gross Profit (p.s.) 0
Sales Per Share 5.77
EBITDA (p.s.) 0.47
Qtrly Earnings Growth -82 %
Operating Cash Flow 18 (M)
Levered Free Cash Flow 19 (M)
Stock Valuations
PE Ratio 42.14
PEG Ratio 0
Price to Book value 8.24
Price to Sales 1.97
Price to Cash Flow 20.45
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android